SCHEMBL18171837

SCHEMBL18171837

CC(C)(C)OC(=O)Cn1c(=O)n(CC(=O)OC(C)(C)C)c2c(Cl)cccc21

nearest known ligand 0.49

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 2/20 0.49
▸ KDM4E B2RXH2 2/20 0.49
▸ NPC1 O15118 1/20 0.43
▸ GAA P10253 1/20 0.43
▸ KMT2A Q03164 2/20 0.42
▸ MEN1 O00255 1/20 0.42
▸ CYP1A2 P05177 2/20 0.40
▸ CYP3A4 P08684 2/20 0.40
▸ CYP2C9 P11712 2/20 0.40
▸ CYP2C19 P33261 2/20 0.40
▸ NPSR1 Q6W5P4 1/20 0.40
▸ CXCR3 P49682 2/20 0.39
▸ CNR2 P34972 2/20 0.39
▸ APEX1 P27695 1/20 0.39
▸ SMN1; SMN2 Q16637 1/20 0.38
▸ CYP2D6 P10635 1/20 0.38
▸ STS P08842 1/20 0.35
▸ PLA2G10 O15496 1/20 0.35
▸ PLA2G5 P39877 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18171779 0.83 ALDH1A1 (0.64) ALDH1A1KDM4ENPC1GAAKMT2A
SCHEMBL18179933 0.79 APEX1 (0.64) ALDH1A1KDM4EKMT2AMEN1CXCR3
SCHEMBL2762363 0.77 ALDH1A1 (0.54) ALDH1A1KDM4ENPC1GAAKMT2A
SCHEMBL2054568 0.77 KDM4E (0.43) ALDH1A1KDM4ENPC1GAAKMT2A
SCHEMBL18171783 0.76 ALDH1A1 (0.46) ALDH1A1KDM4ENPC1GAAKMT2A
SCHEMBL3571941 0.75 ALDH1A1 (0.56) ALDH1A1KDM4ENPC1GAAKMT2A
SCHEMBL261021 0.75 ALDH1A1 (0.43) ALDH1A1KDM4ENPC1GAAKMT2A
SCHEMBL20967569 0.74 ALDH1A1 (0.49) ALDH1A1KDM4ENPC1GAAKMT2A
SCHEMBL261770 0.73 KDM4E (0.41) ALDH1A1KDM4ENPC1GAAKMT2A
SCHEMBL261357 0.72 CALCRL (0.49) ALDH1A1KDM4ENPC1GAAKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180072997-A1 INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION BRISTOL-MYERS SQUIBB COMPANY 2018-03-15 — — US disclosed
EP-3286174-A1 INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION VIIV Healthcare UK (No.5) Limited (GB) 2018-02-28 — — EP disclosed
WO-2016172425-A1 INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION VIIV HEALTHCARE (NO.5) LIMITED (GB) 2016-10-27 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180072997-A1 INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION EIF2AK2, POLR2H, POLR2E ALDH1A1 2545/4885KDM4E 2426/4885NPC1 273/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback